The Tel-Aviv-based medical device company said the MGuard device is wrapped with its MicroNet mesh to prevent embolisms – blood clots – from occurring during and after the placement of a carotid stent.
"When treating carotid arterial disease, close to half of carotid artery stenting procedures cause distal embolic events that may lead to stroke within 30 days," according to a press release. "The MicroNet is designed to hold plaque and thrombus in place against the wall of the blocked artery, preventing debris from falling into the bloodstream and causing a potentially fatal downstream blockage or stroke."
"The CE Mark approval for our MGuard carotid system is a major milestone for the company and is further validation of the MicroNet technology. We look forward to accelerating our clinical development program with our carotid system. The CE Mark should enhance our partnership strategy in the near term," president & CEO Alan Milinazzo said in prepared remarks.